Oncology and Hematology

97-112 of 592

Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
MinuteCE®
Looking Ahead: Integrating CDH6-Targeted Therapies Into Ovarian Cancer Treatment Paradigms
0.50 program credits
- Joyce F. Liu, MD, MPH
- Kathleen Moore, MD, MS
0.50 program credits
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
Project Oncology®
Selecting First-Line Therapy in Gastric Cancers: A Biomarker-Driven Approach
- Jennifer Caudle, DO, FACOFP
- Samuel Klempner, MD
- Nataliya Uboha, MD, PhD
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
Project Oncology®
Assessing Atirmociclib Plus Letrozole in HR+/HER2- Metastatic Breast Cancer
- Pavani Chalasani, MD, MPH
- Antonio Giordano, MD, PhD
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
Project Oncology®
Axatilimab for cGVHD: Assessing Organ-Specific Responses in AGAVE-201
- Charles Turck, PharmD, BCPS, BCCCP
- Shernan Holtan, MD
- Alicia Lieberman, MD, MS
Obesity and Cancer Screening: National Trends and Disparities Revealed
Obesity and Cancer Screening: National Trends and Disparities Revealed
Clinician's Roundtable
Obesity and Cancer Screening: National Trends and Disparities Revealed
- Vance Albaugh, MD, PhD
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
Project Oncology®
Managing MCL After BTKi Failure: The Expanding Role of CAR T-Cell Therapy
- Charles Turck, PharmD, BCPS, BCCCP
- Luhua (Michael) Wang, MD
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
Clinician's Roundtable
Advancing MPE Diagnosis and Prognosis: Clinical Value of Biomarker Integration
- David Feller-Kopman, MD
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
Project Oncology®
Chronic Graft-Versus-Host Disease Care: Evolving Therapeutic Strategies
- Brian P. McDonough, MD, FAAFP
- Doris M. Ponce, MD, MS
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Project Oncology®
Reevaluating Race in Spirometry: Advancing Equity in Pulmonary Risk Assessment
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Project Oncology®
Modernizing Pulmonary Assessment: Reassessing Race-Neutral Interpretation in Practice
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
Project Oncology®
Evaluating Axatilimab in Chronic GVHD: How Prior Therapies Impact Outcomes
- Hallie Blevins, PhD
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
Oncology and Hematology
Adjuvant Pembrolizumab Plus Cisplatin-Based Chemoradiation in Locally Advanced HNSCC: First Results From the Randomized Phase 2b ADRISK Trial
- Yungan Tao
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
Oncology and Hematology
Patient-Reported Outcomes From the Phase 3 KEYNOTE-689 Trial of Adding Perioperative Pembrolizumab to Standard of Care in Resectable Locally Advanced HNSCC
- Yungan Tao
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
Oncology and Hematology
KEYNOTE-717: Randomized Phase 2 Trial of Adding Local Hypofractionated Radiotherapy to Pembrolizumab in Recurrent or Metastatic Head and Neck Cancer
- Prof. Markus Hecht
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Oncology and Hematology
Cohort 9 of the Phase 2 EV-202 Trial: First-Line Enfortumab Vedotin Plus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
- Paul L Swiecicki, MD
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
Oncology and Hematology
Amivantamab Monotherapy or in Combination With Paclitaxel in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: OrigAMI-4 Study Results
- Kevin J Harrington, PhD, FRCP, FRCR, FRSB